Market Place
Sourcing Support
2seventy bio Reports Q3 Financial Results & Operational Progress
12 Nov 2024 //
BUSINESSWIRE
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
26 Sep 2024 //
FIERCE PHARMA
2seventy Bio Reports Q2 Results And Recent Operational Progress
07 Aug 2024 //
BUSINESSWIRE
2sevent sale of Hemophilia A Candidate And Gene Editing Technology to Novo
26 Jun 2024 //
BUSINESSWIRE
2seventy Bio Divests Hemophilia and Gene-Editing to Novo Nordisk
25 Jun 2024 //
FIERCE BIOTECH
EU regulator requires secondary cancer risk warning for CAR-T therapies
15 Jun 2024 //
REUTERS
2seventy bio to Participate in Upcoming Investor Conferences
23 May 2024 //
BUSINESSWIRE
Regeneron cell medicines chief is crafting a new `secret sauce`
09 May 2024 //
FIERCE BIOTECH
2seventy Bio: Q1 Financial Results, Operational Progress
08 May 2024 //
BUSINESSWIRE
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
03 May 2024 //
BUSINESSWIRE
US FDA mandates label updates on CAR-T cancer therapies
19 Apr 2024 //
REUTERS
BMS` Abecma wins earlier myeloma nod with updated boxed warning
06 Apr 2024 //
FIERCE PHARMA
U.S. FDA Approves BMS & 2seventy for Triple-Class Exposed r/r Multiple Myeloma
05 Apr 2024 //
BUSINESSWIRE
2seventy bio Announces Completion of Pipeline Divestiture to Regeneron
01 Apr 2024 //
BUSINESSWIRE
2seventy bio Announces Board of Directors
20 Mar 2024 //
BUSINESSWIRE
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
BUSINESSWIRE
Bristol Myers Squibb and 2seventy bio Share Update on Meeting for Abecma
05 Feb 2024 //
BUSINESSWIRE
2seventy bio to Participate in Upcoming Investor Conferences
05 Feb 2024 //
BUSINESSWIRE
2seventy bio Announces New Strategic Path Forward
31 Jan 2024 //
PRESS RELEASE
Regeneron Announces Formation of Regeneron Cell Medicines
30 Jan 2024 //
GLOBENEWSWIRE
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12
11 Dec 2023 //
BUSINESSWIRE
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
06 Dec 2023 //
BUSINESSWIRE
US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
21 Nov 2023 //
REUTERS
BMS and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma
20 Nov 2023 //
BUSINESSWIRE
2seventy bio Reports Third Quarter Financial Results
14 Nov 2023 //
BUSINESSWIRE
2seventy bio to Report Third Quarter 2023 Financial Results
10 Nov 2023 //
PRESS RELEASE
2seventy bio stock drops 24% as competition catches up with BMS- drug
26 Oct 2023 //
ENDPTS
BMS` manufacturing shutdown means lower-than-expected Q3 sales for Abecma
15 Sep 2023 //
ENDPTS
2seventy bio to lay off 40% of workforce; CEO to step down
13 Sep 2023 //
BUSINESSWIRE
FDA Puts 2seventy bio’s CAR-T Trial on Formal Hold After Patient Death
15 Aug 2023 //
BIOSPACE
2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference
01 Aug 2023 //
BUSINESSWIRE
2Seventy Bio`s partner pauses cancer therapy study after patient death
15 Jun 2023 //
REUTERS
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33
14 Jun 2023 //
BUSINESSWIRE
2seventy bio to Participate in Upcoming Investor Conference
07 Jun 2023 //
PRESS RELEASE
2seventy bio Presents Late-Breaking Results for SC-DARIC33
19 May 2023 //
BUSINESSWIRE
2seventy Presents Data Highlighting Approaches Across Cell Therapies Portfolio
17 May 2023 //
PRESS RELEASE
2seventy bio Announces Additional Data from KarMMa Studies of Abecma
11 May 2023 //
PRESS RELEASE
2seventy Reports First Quarter Financial Results and Recent Operational Progress
03 May 2023 //
PRESS RELEASE
2seventy bio to Present Data from Investigational Cell Therapies at the ASGCT
02 May 2023 //
PRESS RELEASE
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data
01 May 2023 //
PRESS RELEASE
Milestone Monday for Immatics’ Bristol Myers-allied cell therapy & 2seventy bio
01 May 2023 //
ENDPTS
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
28 Apr 2023 //
BUSINESSWIRE
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
BUSINESSWIRE
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
08 Mar 2023 //
BUSINESSWIRE
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
03 Mar 2023 //
BUSINESSWIRE
2seventy bio Announces Proposed Public Offering of Common Stock
28 Feb 2023 //
BUSINESSWIRE
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
28 Feb 2023 //
BUSINESSWIRE
BMS details landmark Abecma myeloma data that ASH turned down
11 Feb 2023 //
FIERCE PHARMA
2seventy bio to Participate in Upcoming Investor Conferences
01 Feb 2023 //
BUSINESSWIRE
2seventy bio Provides Company Outlook for 2023
09 Jan 2023 //
BUSINESSWIRE
2seventy bio Reports Third Quarter Financial Results
07 Nov 2022 //
BUSINESSWIRE
2seventy and JW Therapeutics partner to develop immunotherapies
28 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
2seventy bio and JW Therapeutics Announce Strategic Partnership
27 Oct 2022 //
BUSINESSWIRE
2 biotechs pen licensing pact for cell therapy cancer platform
27 Oct 2022 //
FIERCEBIOTECH
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma
07 Sep 2022 //
BUSINESSWIRE
2seventy bio to Participate in Upcoming Investor Conferences
31 Aug 2022 //
BUSINESSWIRE
BMS touts Abecma`s earlier myeloma win in race with J&J`s CAR-T
11 Aug 2022 //
FIERCE PHARMA
Bristol Myers Squibb & 2seventy Announce Topline Results from KarMMa-3 Trial
10 Aug 2022 //
BUSINESS WIRE
2seventy bio Reports Second Quarter Financial Results
10 Aug 2022 //
BUSINESS WIRE
Insiders of 2seventy bio, Inc. received good value on their investment
08 Jul 2022 //
SIMPLYWALL
